We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




BD to Supply Molecular Platform to BioReference

By HospiMedica staff writers
Posted on 07 Jul 2006
BD Diagnostics, a segment of Becton, Dickinson and Company (BD, Franklin Lakes, NJ; USA), has signed an agreement with BioReference Laboratories (BLRI, Elmwood Park, NJ, USA) whereby BD will supply BLRI with instrumentation and reagents for testing sexually transmitted infections (STIs).

Under the agreement, testing for Chlamydia trachomatis and Neisseria gonorrhoeae will be run on the Scara robotic automation platform of the BD Viper system. More...
BD will be the primary supplier to BioReference for testing these two diseases.

The BD Viper system incorporates a Scara robot that delivers robust performance by eliminating all pumps, syringes, and tubing that were a major weakness of earlier-generation molecular automation. The isothermal, real-time amplification and detection offered by BD's strand displacement amplification (SDA) has greatly simplified complex molecular testing and made this technology more accessible to clinical laboratories.

Early and accurate diagnosis of sexually transmitted infections, specifically chlamydia and gonorrhea, leads to more timely and effective treatment, reduces the potential for further spread of infection, and helps insure better patient outcomes. Left untreated in women, chlamydia can lead to infertility, ectopic pregnancy, and debilitating pelvic pain.

BD is a medical technology company that makes and sells medical devices, instrument systems, and reagents. The company is focused on enhancing the quality and speed of diagnosing infectious diseases, improving drug therapy, advancing research, and the discovery of new drugs and vaccines. It serves healthcare institutions, life science researchers, clinical laboratories, industry, and the general public.



Related Links:
Becton, Dickinson and Company
BioReference Laboratories

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.